Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Study of GFB-887 in Glomerular Kidney Diseases
NCT04950114Phase 2Terminated
- Sponsor
- Goldfinch Bio
- Start
- Jul 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GFB-887 in focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD), sponsored by Goldfinch Bio. Primary endpoint: Incidence and severity of adverse events at 3 years. Started Jul 2021; status: terminated.
02
Drugs
GFB-887
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)
Beyond the preview
Go deeper on NCT04950114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950114.